Christopher Bowden's Insider Trades & SAST Disclosures
Christopher Bowden's most recent trade in Alaunos Therapeutics Inc was a trade of 100,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on June 22, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Christopher Bowden.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alaunos Therapeutics Inc | Christopher Bowden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Alaunos Therapeutics Inc | Christopher Bowden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 40,000 | 44,167 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.11 per share. | 18 Jun 2021 | 48,493 | 15,487 (0%) | 0% | 60.1 | 2,914,851 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 50.40 per share. | 18 Jun 2021 | 46,608 | 63,980 (0%) | 0% | 50.4 | 2,349,043 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2021 | 46,608 | 992 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2021 | 1,885 | 0 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 18 Jun 2021 | 1,885 | 17,372 (0%) | 0% | 39.8 | 74,948 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 17 Jun 2021 | 2,502 | 17,989 (0%) | 0% | 39.8 | 99,480 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 2,502 | 1,885 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.02 per share. | 17 Jun 2021 | 2,502 | 15,487 (0%) | 0% | 60.0 | 150,170 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2021 | 20,853 | 4,387 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.06 per share. | 09 Jun 2021 | 20,853 | 15,487 (0%) | 0% | 60.1 | 1,252,437 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 09 Jun 2021 | 20,853 | 36,340 (0%) | 0% | 39.8 | 829,115 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 09 Jun 2021 | 7,149 | 22,636 (0%) | 0% | 39.8 | 284,244 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2021 | 7,149 | 25,240 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.16 per share. | 09 Jun 2021 | 7,149 | 15,487 (0%) | 0% | 60.2 | 430,117 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 6,675 | 32,389 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.07 per share. | 07 Jun 2021 | 6,675 | 15,487 (0%) | 0% | 60.1 | 400,939 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 07 Jun 2021 | 6,675 | 22,162 (0%) | 0% | 39.8 | 265,398 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.04 per share. | 07 Jun 2021 | 4,268 | 15,487 (0%) | 0% | 60.0 | 256,232 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 4,268 | 39,064 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 07 Jun 2021 | 4,268 | 19,755 (0%) | 0% | 39.8 | 169,696 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 55.11 per share. | 19 Apr 2021 | 14,401 | 15,487 (0%) | 0% | 55.1 | 793,582 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2021 | 12,513 | 0 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.16 per share. | 19 Apr 2021 | 12,513 | 28,000 (0%) | 0% | 35.2 | 439,957 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2021 | 3,210 | 12,513 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 55.16 per share. | 19 Apr 2021 | 3,210 | 15,487 (0%) | 0% | 55.2 | 177,055 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.16 per share. | 19 Apr 2021 | 3,210 | 18,697 (0%) | 0% | 35.2 | 112,864 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2021 | 1,888 | 43,332 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 19 Apr 2021 | 1,888 | 29,888 (0%) | 0% | 39.8 | 75,067 | Common stock |
| Alaunos Therapeutics Inc | Christopher Bowden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 31,250 | 31,250 | - | - | Stock Option (right to buy) | |
| Alaunos Therapeutics Inc | Christopher Bowden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 4,167 | 4,167 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 3,334 | 16,396 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 3,334 | 3,333 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 22 Feb 2021 | 986 | 15,410 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 4,000 | 12,381 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 4,000 | 8,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 2,750 | 15,131 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 2,750 | 0 | - | - | Restricted stock unit | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 14 Feb 2021 | 2,069 | 13,062 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 44,000 | 44,000 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 11,000 | 11,000 | - | - | Restricted stock units | |
| Viridian Therapeutics Inc | Christopher Bowden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2020 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2020 | 3,583 | 15,723 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 50.01 per share. | 20 May 2020 | 3,583 | 8,306 (0%) | 0% | 50.0 | 179,200 | Common stock |
| Agios Pharmaceuticals Inc | Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.16 per share. | 20 May 2020 | 3,583 | 11,889 (0%) | 0% | 35.2 | 125,978 | Common stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges